National Heart, Lung, and Blood Institute cardiovascular clinical trial perspective - 19/06/20
Doi : 10.1016/j.ahj.2020.02.014
Gail D. Pearson, MD, ScD a, ⁎ 
, George A. Mensah, MD b, Yves Rosenberg, MD, MPH a, Catherine M. Stoney, PhD a, Katherine Kavounis, MPH a, David C. Goff, MD, PhD a
, George A. Mensah, MD b, Yves Rosenberg, MD, MPH a, Catherine M. Stoney, PhD a, Katherine Kavounis, MPH a, David C. Goff, MD, PhD a a Division of Cardiovascular Sciences, NHLBI
b Center for Translational Research and Implementation Science, NHLBI
⁎Reprint requests: Gail D. Pearson, MD, ScD, Division of Cardiovascular Sciences, NHLBI.Division of Cardiovascular Sciences, NHLBI
Abstract |
The National Heart, Lung, and Blood Institute (NHLBI) has played an important role in funding the clinical science that supports many contemporary cardiology practice guidelines and in shaping the conduct of cardiovascular clinical trials. This Perspective outlines contemporary funding options as well as select important NHLBI policies, philosophy, and priorities.
Le texte complet de cet article est disponible en PDF.Plan
| ☆ | Disclaimer: The views expressed in this article are those of the authors, and do not represent official positions of the National Heart, Lung, and Blood Institute, NIH or DHHS. |
© 2020
Publié par Elsevier Masson SAS.
Vol 224
P. 25-34 - juin 2020 Retour au numéro
Article précédent
- Precision medicine in distinct heart failure phenotypes: Focus on clinical epigenetics
- Claudio Napoli, Giuditta Benincasa, Francesco Donatelli, Giuseppe Ambrosio
- Racial disparities and democratization of health care: A focus on TAVR in the United States
- David R. Holmes, Michael J. Mack, Mohamad Alkhouli, Sreekanth Vemulapalli
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?